These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 37691291)

  • 41. Nonalcoholic steatohepatitis and diabetes.
    Caballeria J; Caballeria L
    Endocrinol Nutr; 2016 Oct; 63(8):377-9. PubMed ID: 27423933
    [No Abstract]   [Full Text] [Related]  

  • 42. Mitochondrial dysfunction in steatotic rat livers occurs because a defect in complex i makes the liver susceptible to prolonged cold ischemia.
    Chu MJ; Hickey AJ; Jiang Y; Petzer A; Bartlett AS; Phillips AR
    Liver Transpl; 2015 Mar; 21(3):396-407. PubMed ID: 25312517
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Metabolic dysfunction associated fatty liver disease: The new nomenclature and its impact.
    Tang SY; Tan JS; Pang XZ; Lee GH
    World J Gastroenterol; 2023 Jan; 29(3):549-560. PubMed ID: 36688021
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pediatric non-alcoholic fatty liver disease: Recent solutions, unresolved issues, and future research directions.
    Clemente MG; Mandato C; Poeta M; Vajro P
    World J Gastroenterol; 2016 Sep; 22(36):8078-93. PubMed ID: 27688650
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Editorial: liver stiffness by magnetic resonance elastography and cardiovascular risk in non-alcoholic fatty liver disease-simply associated or more complicated? Authors' reply.
    Park JG; Jung J; Loomba R
    Aliment Pharmacol Ther; 2021 Jun; 53(11):1230-1231. PubMed ID: 33961702
    [No Abstract]   [Full Text] [Related]  

  • 46. [Diagnosis and evaluation of metabolic dysfunction associated steatotic liver disease (MASLD)].
    Canivet CM; Faure S
    Rev Med Interne; 2024 Jan; 45(1):41-47. PubMed ID: 38158295
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Non-alcoholic fatty liver disease and cardiovascular risk: an update.
    Mullish BH; Forlano R; Manousou P; Mikhailidis DP
    Expert Rev Gastroenterol Hepatol; 2018 Dec; 12(12):1175-1177. PubMed ID: 30791787
    [No Abstract]   [Full Text] [Related]  

  • 48. Cardiovascular outcomes post bariatric surgery in patients with metabolic dysfunction-associated steatotic liver disease - A systematic review and meta-analysis.
    Kumar J; Mohsin S; Hasan M; Bilal AR; Ali KM; Umer A; Hadi DZM; Nandlal S; Kumar S
    Clin Res Hepatol Gastroenterol; 2024 Jan; 48(1):102261. PubMed ID: 38070828
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome.
    Yki-Järvinen H
    Lancet Diabetes Endocrinol; 2014 Nov; 2(11):901-10. PubMed ID: 24731669
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Incidence and Risks for Nonalcoholic Fatty Liver Disease and Steatohepatitis Post-liver Transplant: Systematic Review and Meta-analysis.
    Saeed N; Glass L; Sharma P; Shannon C; Sonnenday CJ; Tincopa MA
    Transplantation; 2019 Nov; 103(11):e345-e354. PubMed ID: 31415032
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Brazilian evidence-based guideline for screening, diagnosis, treatment, and follow-up of metabolic dysfunction-associated steatotic liver disease (MASLD) in adult individuals with overweight or obesity: A joint position statement from the Brazilian Society of Endocrinology and Metabolism (SBEM), Brazilian Society of Hepatology (SBH), and Brazilian Association for the Study of Obesity and Metabolic Syndrome (Abeso).
    Moreira RO; Valerio CM; Villela-Nogueira CA; Cercato C; Gerchman F; Lottenberg AMP; Godoy-Matos AF; Oliveira RA; Brandão Mello CE; Álvares-da-Silva MR; Leite NC; Cotrim HP; Parisi ER; Silva GF; Miranda PAC; Halpern B; Pinto Oliveira C
    Arch Endocrinol Metab; 2023 Nov; 67(6):e230123. PubMed ID: 38048417
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Frequency of Cardiovascular Events and Effect on Survival in Liver Transplant Recipients for Cirrhosis Due to Alcoholic or Nonalcoholic Steatohepatitis.
    Piazza NA; Singal AK
    Exp Clin Transplant; 2016 Feb; 14(1):79-85. PubMed ID: 26581602
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The association between metabolic dysfunction-associated steatotic liver disease, cardiovascular and cerebrovascular diseases and the thickness of carotid plaque.
    Huang Y; Wang Y; Xiao Z; Yao S; Tang Y; Zhou L; Wang Q; Xie Y; Zhang L; Zhou Y; Lu Y; Zhu W; Chen M
    BMC Cardiovasc Disord; 2023 Nov; 23(1):554. PubMed ID: 37951879
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pediatric nonalcoholic fatty liver disease, metabolic syndrome and cardiovascular risk.
    Pacifico L; Nobili V; Anania C; Verdecchia P; Chiesa C
    World J Gastroenterol; 2011 Jul; 17(26):3082-91. PubMed ID: 21912450
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hyperuricaemia and non-alcoholic fatty liver disease (NAFLD): a relationship with implications for vascular risk?
    Katsiki N; Athyros VG; Karagiannis A; Mikhailidis DP
    Curr Vasc Pharmacol; 2011 Nov; 9(6):698-705. PubMed ID: 21388346
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Effect of the nomenclature of non-alcoholic fatty liver disease on diagnosis and treatment of fatty liver disease concomitant with other liver diseases].
    Chen L; Jiang LN; Zhao JM
    Zhonghua Gan Zang Bing Za Zhi; 2023 Aug; 31(8):805-809. PubMed ID: 37723061
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Non alcoholic fatty liver disease: a new risk factor for cardiovascular disease?].
    Sdiri W; Romdhane H; Mbarek D; Ben Abdallah H; Longo S; Abdelli MN; Boujnah MR
    Tunis Med; 2013 Mar; 91(3):171-4. PubMed ID: 23588628
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Non-alcoholic fatty liver disease and cardiovascular disease: epidemiological, clinical and pathophysiological evidences.
    Del Ben M; Baratta F; Polimeni L; Angelico F
    Intern Emerg Med; 2012 Oct; 7 Suppl 3():S291-6. PubMed ID: 23073870
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Application of Machine Learning Methods to Predict Non-Alcoholic Steatohepatitis (NASH) in Non-Alcoholic Fatty Liver (NAFL) Patients.
    Fialoke S; Malarstig A; Miller MR; Dumitriu A
    AMIA Annu Symp Proc; 2018; 2018():430-439. PubMed ID: 30815083
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Hepatic steatosis and cardiovascular disease outcomes: An analysis of the Framingham Heart Study.
    Mellinger JL; Pencina KM; Massaro JM; Hoffmann U; Seshadri S; Fox CS; O'Donnell CJ; Speliotes EK
    J Hepatol; 2015 Aug; 63(2):470-6. PubMed ID: 25776891
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.